SEC Form 4 · accession 0001209191-16-156654
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Charles Gorman
Officer — President and CEO · Director
Period of report
Dec 23, 2016
Accepted (ET)
Dec 23, 2016 · 3:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 23, 2016 | M | 9,100 | $2.59 | A | 237,177 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $2.59 | Dec 23, 2016 | M | 9,100 | D | — | May 11, 2017 | Common Stock | 9,100 | 85,900 | D |
Explanation of responses
- F1The option was granted May 11, 2010 and vested in 36 equal monthly installments beginning June 11, 2010.